Novo Nordisk defended disappointing trial results for its obesity drug candidate CagriSema, emphasizing its importance as a weight loss treatment despite underwhelming outcomes in late-stage trials. CEO Lars Fruergaard Jørgensen acknowledged the share price impact but expressed confidence in CagriSema’s potential, reassuring shareholders at the Annual General Meeting in Copenhagen, Denmark that it will be a significant product for the company.
Full Article
Loading PerspectiveSplit analysis...
